PERSISTENCE TO DENOSUMAB IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS AT INCREASED FRACTURE RISK TREATED IN ROUTINE CLINICAL PRACTICE IN BULGARIA

被引：0
|
作者：
Monov, S. [1 ]
Nestorova, R. [2 ]
Velkova, M. [3 ]
Temelkova, N. [4 ]
Jeleva, S. [5 ]
Petkova, R. [6 ]
Petranova, T. [1 ]
机构：
[1] Med Univ, Clin Rheumatol, Sofia, Bulgaria
[2] ASIMP RC St Irina, Sofia, Bulgaria
[3] ASIMP Rheumatol, Russe, Bulgaria
[4] Univ Hosp Alexandrovska, Sofia, Bulgaria
[5] Med Ctr Orfey, St Zagora, Bulgaria
[6] Amgen Bulgaria, Sofia, Bulgaria
来源：
OSTEOPOROSIS INTERNATIONAL | 2020年 / 31卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P856
引用
收藏
页码：S442 / S443
页数：2
相关论文
共 50 条
  • [41] Lifetime Risk of Fracture Among Postmenopausal Women With Osteoporosis And at High Risk of Fracture
    Brunetti, Vanessa C.
    Chien, Hsu-Chih
    McDermott, Michele
    Lin, Tzu-Chieh
    Kim, Min
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 573 - 574
  • [42] LIFETIME RISK OF FRACTURE AMONG POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AND AT HIGH RISK OF FRACTURE
    Brunetti, V. C.
    Chien, H-C
    Mcdermott, M.
    Lin, T-C
    Kim, M.
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 : S582 - S583
  • [43] Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
    McClung, Michael R.
    Williams, Gregory C.
    Hattersley, Gary
    Fitzpatrick, Lorraine A.
    Wang, Yamei
    Miller, Paul D.
    CALCIFIED TISSUE INTERNATIONAL, 2018, 102 (06) : 627 - 633
  • [44] Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
    Stuart L. Silverman
    E. Siris
    D. Belazi
    C. Recknor
    A. Papaioannou
    J. P. Brown
    D. T. Gold
    E. M. Lewiecki
    G. Quinn
    A. Balasubramanian
    S. Yue
    B. Stolshek
    D. L. Kendler
    Archives of Osteoporosis, 2018, 13
  • [45] Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
    Silverman, Stuart L.
    Siris, E.
    Belazi, D.
    Recknor, C.
    Papaioannou, A.
    Brown, J. P.
    Gold, D. T.
    Lewiecki, E. M.
    Quinn, G.
    Balasubramanian, A.
    Yue, S.
    Stolshek, B.
    Kendler, D. L.
    ARCHIVES OF OSTEOPOROSIS, 2018, 13 (01)
  • [46] Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis
    Okawa, Tokutaro
    Okawa, Motomi
    Koike, Tatsuya
    JOURNAL OF BONE AND MINERAL METABOLISM, 2022, 40 (06) : 960 - 967
  • [47] Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis
    Tokutaro Okawa
    Motomi Okawa
    Tatsuya Koike
    Journal of Bone and Mineral Metabolism, 2022, 40 : 960 - 967
  • [48] COMPARING CLINICAL AND ECONOMIC OUTCOMES OF DENOSUMAB AND TERIPARATIDE MEDICATIONS IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    Elsalmawy, A. H. E.
    OSTEOPOROSIS INTERNATIONAL, 2018, 29 : S219 - S219
  • [49] THE EFFECTS OF TWICE-YEARLY DENOSUMAB ON FRACTURE RISK IN WOMEN WITH OSTEOPOROSIS
    Cummings, S.
    Zanchetta, J.
    McClung, M.
    Christiansen, C.
    Siris, E.
    Delmas, P. D.
    Eastell, R.
    Adami, S.
    Kutilek, S.
    Reid, I.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 16 - 16
  • [50] Are women with osteoporosis treated with denosumab at risk of severe COVID-19?
    Formenti, Anna Maria
    Pedone, Erika
    di Filippo, Luigi
    Ulivieri, Fabio Massimo
    Giustina, Andrea
    ENDOCRINE, 2020, 70 (02) : 203 - 205
12345